A Study of Carbon-14-Labelled [14C] LY3437943 in Healthy Male Participants

Part of paid clinical trials in Madison, Wisconsin.

Sponsor
Eli Lilly and Company
Study ID
NCT05757531
Phase
PHASE1
Status
Completed

Conditions

  • Healthy

Eligibility Criteria

Sex
MALE
Age
18 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

  • [¹⁴C]-LY3437943 — DRUG
    Administered SC.

Study Details

The main purpose of this study is to is to look at how much LY3437943 gets into the bloodstream and how long the body takes to get rid of it in healthy male participants. This study will involve a single dose of 14C radiolabeled LY3437943. his means that a radioactive tracer substance, C14, will be incorporated into the study drug to investigate the study drug and its breakdown products and to find out how much of these pass from blood into urine, feces and expired air. The study will last up to approximately 15 weeks including the screening period of 28 days.

Key Dates

Start date
Mar 17, 2023
Status verified
Jul 2023
Primary completion
Jun 23, 2023
Completion
Jun 23, 2023

Study Design

Enrollment
7 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: [¹⁴C]-LY3437943
    Single dose of \[¹⁴C\]-LY3437943 administered subcutaneously (SC).

Primary Outcome Measure

Urinary Excretion of LY3437943 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered [ Time Frame: Predose up to 63 days post dose ]

Locations (1)

FacilityCityStateZIPSite coordinators
Covance Clinical Research UnitMadisonWisconsin53704-

Find similar trials in Madison, WI

By research site
Covance Clinical Research Unit· Madison, WI

Related Studies